Network pharmacology approaches for research of Traditional Chinese Medicines

被引:199
作者
Li, Xiang [1 ,2 ,3 ]
Liu, Ziqi [2 ]
Liao, Jie [2 ,3 ,4 ]
Chen, Qian [2 ,3 ,4 ]
Lu, Xiaoyan [2 ,3 ,4 ]
Fan, Xiaohui [2 ,3 ,4 ]
机构
[1] Hangzhou Med Coll, Sch Basic Med Sci & Forens Med, Hangzhou 311399, Peoples R China
[2] Zhejiang Univ, Coll Pharmaceut Sci, Dept Chinese Med Sci & Engn, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, State Key Lab Component based Chinese Med, Innovat Ctr, Hangzhou 310058, Peoples R China
[4] Zhejiang Univ, Innovat Ctr Yangtze River Delta, Future Hlth Lab, Jiaxing 314100, Peoples R China
关键词
Network Pharmacology; Single-Cell omics; Artificial Intelligence; Traditional Chinese Medicine; Herbal Medicine; Pharmacodynamics Material Basis; Effective Mechanism; Drug Repurposing; MECHANISMS; DATABASE; SERVER; GENES;
D O I
10.1016/S1875-5364(23)60429-7
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Pharmacodynamics material basis and effective mechanisms are the two main issues to decipher the mechnisms of ac-tion of Traditional Chinese medicines (TCMs) for the treatment of diseases. TCMs, in "multi-component, multi-target, multi-pathway" paradigm, show satisfactory clinical results in complex diseases. New ideas and methods are urgently needed to explain the complex interactions between TCMs and diseases. Network pharmacology (NP) provides a novel paradigm to uncover and visualize the under-lying interaction networks of TCMs against multifactorial diseases. The development and application of NP has promoted the safety, efficacy, and mechanism investigations of TCMs, which then reinforces the credibility and popularity of TCMs. The current organ-centricity of medicine and the "one disease-one target-one drug" dogma obstruct the understanding of complex diseases and the devel-opment of effective drugs. Therefore, more attentions should be paid to shift from "phenotype and symptom" to "endotype and cause" in understanding and redefining current diseases. In the past two decades, with the advent of advanced and intelligent technologies (such as metabolomics, proteomics, transcriptomics, single-cell omics, and artificial intelligence), NP has been improved and deeply implemented, and presented its great value and potential as the next drug-discovery paradigm. NP is developed to cure causal mechan-isms instead of treating symptoms. This review briefly summarizes the recent research progress on NP application in TCMs for effic-acy research, mechanism elucidation, target prediction, safety evaluation, drug repurposing, and drug design.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 93 条
[1]   OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders [J].
Amberger, Joanna S. ;
Bocchini, Carol A. ;
Schiettecatte, Francois ;
Scott, Alan F. ;
Hamosh, Ada .
NUCLEIC ACIDS RESEARCH, 2015, 43 (D1) :D789-D798
[2]   An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy [J].
Bai, Zhenyu ;
Xie, Ting ;
Liu, Tianhao ;
Chen, Zedong ;
Yu, Linde ;
Zhang, Chao ;
Luo, Jincheng ;
Chen, Liguo ;
Zhao, Xiaoshan ;
Xiao, Ya .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[3]   From single drug targets to synergistic network pharmacology in ischemic stroke [J].
Casas, Ana I. ;
Hassan, Ahmed A. ;
Larsen, Simon J. ;
Gomez-Rangel, Vanessa ;
Elbatreek, Mahmoud ;
Kleikers, Pamela W. M. ;
Guney, Emre ;
Egea, Javier ;
Lopez, Manuela G. ;
Baumbach, Jan ;
Schmidt, Harald H. H. W. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (14) :7129-7136
[5]   Integrated lipidomics and network pharmacology analysis to reveal the mechanisms of berberine in the treatment of hyperlipidemia [J].
Chen, Yuting ;
Li, Kaipeng ;
Zhao, Han ;
Hao, Zhangsen ;
Yang, Yuxin ;
Gao, Mingming ;
Zhao, Ding .
JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
[6]   TCM Made in China [J].
Cheung, Felix .
NATURE, 2011, 480 (7378) :S82-S83
[7]   The Use of Artificial Intelligence in Complementary and Alternative Medicine: A Systematic Scoping Review [J].
Chu, Hongmin ;
Moon, Seunghwan ;
Park, Jeongsu ;
Bak, Seongjun ;
Ko, Youme ;
Youn, Bo-Young .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[8]   Comparative Toxicogenomics Database (CTD): update 2023 [J].
Davis, Allan Peter ;
Wiegers, Thomas C. ;
Johnson, Robin J. ;
Sciaky, Daniela ;
Wiegers, Jolene ;
Mattingly, Carolyn J. .
NUCLEIC ACIDS RESEARCH, 2023, 51 (D1) :D1257-D1262
[9]   The IntAct database: efficient access to fine-grained molecular interaction data [J].
del Toro, Noemi ;
Shrivastava, Anjali ;
Ragueneau, Eliot ;
Meldal, Birgit ;
Combe, Colin ;
Barrera, Elisabet ;
Perfetto, Livia ;
How, Karyn ;
Ratan, Prashansa ;
Shirodkar, Gautam ;
Lu, Odilia ;
Meszaros, Balint ;
Watkins, Xavier ;
Pundir, Sangya ;
Licata, Luana ;
Iannuccelli, Marta ;
Pellegrini, Matteo ;
Martin, Maria Jesus ;
Panni, Simona ;
Duesbury, Margaret ;
Vallet, Sylvain D. ;
Rappsilber, Juri ;
Ricard-Blum, Sylvie ;
Cesareni, Gianni ;
Salwinski, Lukasz ;
Orchard, Sandra ;
Porras, Pablo ;
Panneerselvam, Kalpana ;
Hermjakob, Henning .
NUCLEIC ACIDS RESEARCH, 2022, 50 (D1) :D648-D653
[10]  
Fan Xiaohui, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2920